Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.38 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13484242 | 0.81 | HTR2A (0.41) | HTR2AHTR2CHTR2BSLC6A2SLC6A4 | |
| SCHEMBL20408746 | 0.81 | HTR2A (0.41) | HTR2AHTR2CHTR2BSLC6A2SLC6A4 | |
| SCHEMBL20408754 | 0.81 | HTR2A (0.41) | HTR2AHTR2CHTR2BSLC6A2SLC6A4 | |
| SCHEMBL13484238 | 0.79 | ESR2 (0.44) | — | |
| SCHEMBL13484240 | 0.79 | ESR2 (0.44) | — | |
| SCHEMBL20408755 | 0.79 | ESR2 (0.44) | — | |
| SCHEMBL20408742 | 0.79 | KDM1A (0.47) | HTR2AHTR2CHTR2BSLC6A2SLC6A4 | |
| SCHEMBL5019134 | 0.78 | TSHR (0.44) | HTR2AHTR2CHTR2BCHRNA7TAAR1 | |
| SCHEMBL17029480 | 0.78 | TSHR (0.44) | HTR2AHTR2CHTR2BCHRNA7TAAR1 | |
| SCHEMBL19775615 | 0.78 | TSHR (0.44) | HTR2AHTR2CHTR2BCHRNA7TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180207153-A1 | UREA DERIVATIVE OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2018-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180207153-A1 | UREA DERIVATIVE OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | FPR1, FPR2, SAAL1 | HTR2A 2130/4885HTR2C 2364/4885HTR2B 1518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.